Epithelial cell-cell adhesion molecule (Ep-CAM)

Similar documents
Cytokeratin 19 (CK19)

Assessment Run CK19

Estrogen receptor (ER)

Thyroid transcription factor-1 (TTF1) Assessment run

Carcinoembryonic antigen (CEA)

Assessment Run GATA3

Sal-like protein 4 (SALL4)

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

SMH (Myosin, smooth muscle heavy chain)

Assessment Run

Assessment Run NKX3.1 (NKX3.1)

Estrogen receptor (ER)

Lung Anaplastic Lymphoma Kinase (lu-alk)

Estrogen receptor (ER)

Assessment Run C1 2017

Assessment Run B HER2 IHC

Assessment Run B HER2 IHC

Assessment Run C3 2018

Assessment Run B HER-2

HER2 ISH (BRISH or FISH)

Optimization of antibodies, selection, protocols and controls Breast tumours

NordiQC - update

External Quality Assessment of melanocytic marker analyses NordiQC experience

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Nordic Immunohistochemical Quality Control

IHC Stainer platforms. Overview, pros and cons

External Quality Assessment of Breast Marker Analysis. NordiQC data

Diagnostic IHC in lung and pleura pathology

Product Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue

NordiQC External Quality Assurance in Immunohistochemistry

10 years of NordiQC Why are 30% of labs still getting it wrong?

Quality Assurance in Immunohistochemistry: Experiences from NordiQC

Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA

Immunohistochemical principles The technical test approach. Pre-analytical parametres

The impact of proficiency testing on lab immunoassays

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)

Results you can trust

Immunocytochemistry. Run 119/48. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Workflow. Connecting the Pieces For Total Patient Care

Supplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in

Image analysis in IHC overview, considerations and applications

Assessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver

Classification of the unknown primary tumour: the primary IHC panel

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)

IDH1 R132H/ATRX Immunohistochemical validation

Immunotherapy in NSCLC Pathologist role

Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Quality Control/Quality Assurance in Diagnostic Immunohistochemistry

npod Viral Workgroup IHC studies update Dr Sarah Richardson

Supplementary Appendix

Immunohistochemistry on Fluid Specimens: Technical Considerations

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

HPV/p16 Analyte Control

Anti-PD-L1 antibody [28-8] ab205921

Supplementary Online Content

Immunocytochemistry. Run 120/49. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment

Immunocytochemistry. Run 113/42. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

HistoCyte Laboratories Ltd

PD-L1 Analyte Control DR

Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we

Interobserver Agreement and Assay Reproducibility of Folate Receptor a Expression in Lung Adenocarcinoma

Milestones in Her 2 Testing

Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods

Product Introduction

ONCO TEAM DIAGNOSTIC

Speaking to you. This statement by Dr. Rodney T. Miller, Director of

Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

Single and Multiplex Immunohistochemistry

VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue

Patterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Immunocytochemistry. Results - Summary Graphs - Pass Rates Best Methods - Selected Images. Run 100. Assessment Dates: 3 rd - 22 nd January 2013

What kind of material should we use for ICC in our daily routine. Torill Sauer Department of Pathology, Akershus University Hospital

Renal System Physiology

Supplementary Online Content

A National Quality Assurance program for breast immunohistochemistry: an Italian perspective

Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

NSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia

Urinary System Laboratory

Renal Physiology Part II. Bio 219 Napa Valley College Dr. Adam Ross

Clinical utility of cancer biomarkers assessed by virtual microscopy

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

April 08, biology 2201 ch 11.3 excretion.notebook. Biology The Excretory System. Apr 13 9:14 PM EXCRETORY SYSTEM.

Stromal CD10 immunohistochemical expression in urothelial carcinoma of urinary bladder and correlation with clinicopathological parameters

014 Chapter 14 Created: 9:25:14 PM CST

Fast, automated, precise

Review of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo

CIHRT Exhibit P-1830 Page 1

Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use

Transcription:

Assessment Run 3 011 Epithelial cell-cell adhesion molecule (Ep-CAM) Material The slide to be stained for Ep-CAM comprised: 1. Appendix,. Kidney, 3. Adrenal gland, 4. Lung carcinoid, 5 & 6. Renal clear cell carcinoma. All tissues were fixed in 10% neutral buffered formalin. Criteria for assessing an Ep-CAM staining as optimal included: A strong, distinct, predominantly membranous staining of virtually all the columnar epithelial cells of the appendix. A moderate to strong predominantly membranous staining of the epithelial cells of the renal collecting tubules, and an at least weak basolateral staining of the epithelial cells of the proximal tubules of the kidney. A moderate to strong, distinct, predominantly membranous staining of virtually all the neoplastic cells of the lung carcinoid. An at least weak predominantly membranous staining of scattered neoplastic cells in the two renal cell carcinomas. 145 laboratories participated in this assessment. 4 laboratories used an inappropriate Ab. Out of the remaining 141 labs 45 % achieved a sufficient mark. In table 1 the antibodies (Abs) used and marks are summarized. Table 1. Abs and assessment marks for EpCAM, run 3 Concentrated Abs N Vendor Optimal Good Borderl. Poor Suff. 1 EP4 MOC-31 VU-1D9 90 3 1 8 3 1 Dako NeoMarkers Diagnostic Biosystems Master Diagnostica Dako Leica/Novocastra Euro-Diagnostika Euro-Diagnostika NeoMarkers Suff. OPS 10 8 34 4 40 % 8 % 4 3 3 58 % 100 % 1 1 0 - - r E144 1 Abcam 0 0 0 1 - - Ready-To-Use Abs EP4 IS/IR637 EP4 760-4383 EP4 48M-97 EP4 N1554 31 790-4561 31 PM403 MOC- MOC- MOC- 31 MON-RTU1097 14 Dako 1 1 1 0 93 % 9 % 8 Ventana/Cell Marque 0 1 3 4 13 % - 1 Cell Marque 0 0 1 0 - - 1 Dako 0 0 0 1 - - Ventana 0 0 0 - - 1 Biocare 1 0 0 0 - - 1 Monosan 0 0 0 1 - - Total 141 18 45 44 34 - - Proportion 13 % 3 % 31 % 4 % 45 % 1) Proportion of sufficient stains (optimal or good) ) Proportion of sufficient stains with optimal protocol settings only, see below. Nordic Immunohistochemical Quality Control, Ep-CAM run 3 011 Page 1 of 5

Following central protocol parameters were used to obtain an optimal staining: Concentrated Abs EP4: The protocols giving an optimal result were all based on heat induced epitope retrieval (HIER) using either Target Retrieval Solution (TRS) low ph 6.1 (Dako) (8/1)* or Diva Decloaker ph 6. (Biocare) (/) as the retrieval buffer. The mab was typically diluted in the range of 1:50-1:400 depending on the total sensitivity of the protocol employed. Using these protocol settings 18 out of (8 %) laboratories produced a sufficient staining (optimal or good). *(number of optimal results/number of laboratories using this buffer) MOC-31: The protocols giving an optimal result were all based on HIER using either TRS high ph 9 (3-in-1) (Dako) (1/1), TRS high ph 9 (Dako) (1/1), TRS low ph 6.1 (Dako) (1/) or EDTA/EGTA ph 8 (1/1) as the retrieval buffer. The mab was typically diluted in the range of 1:0-1:50 depending on the total sensitivity of the protocol employed. Using these protocol settings 8 out of 8 (100 %) laboratories produced a sufficient staining. VU-1D9: The protocols giving an optimal result were all based on HIER using Cell Conditioning 1 (BenchMark, Ventana (1/3)) or Citrate ph 6 (1/1) as the retrieval buffer. The mab was typically diluted in the range of 1:0-1:100 depending on the total sensitivity of the protocol employed. Using these protocol settings 3 out of 4 (75 %) laboratories produced a sufficient staining. Ready-To-Use Abs EP4 (prod. no. IS/IR637, Dako): The protocol giving an optimal result was based on HIER in PT- Link using TRS low ph 6.1 and an incubation time of 0 min. in the primary Ab and EnVision Flex (K8000) as the detection system. Using these protocol settings 1 out of 13 (9 %) laboratories produced a sufficient staining (optimal or good). MOC-31 (prod. no. PM403, Biocare): The protocol giving an optimal result was based on proteolytic pre-treatment using Pepsin 0 for min. at room temperature, an incubation time of 45 min. in the primary Ab and MACH4 (4U534) as the detection system The most frequent causes of insufficient stains were: - Inappropriate HIER buffer (an alkaline buffer for the EP4) - Less successful performance of the EP4 on the BenchMark, Ventana platform. - Proteolytic pre-treatment - Too low concentration of the primary Ab - Use of low sensitive detection systems In this assessment and in concordance to the previous NordiQC assessments, virtually all laboratories were able to demonstrate Ep-CAM in the columnar epithelial cells of the appendix, whereas the prevalent feature of the insufficient staining results was a too weak or false negative staining of the neoplastic cells of the lung carcinoid and in particular of the two renal cell carcinomas. For the most widely used EP4 the proportion of sufficient results was highly influenced by the pre-treatment applied and the IHC platform used. First of all the pass rate was significantly lower if proteolytic pre-treatment was used compared to HIER. If proteolytic pretreatment was used 10 out of 36 protocols (8 %) were assessed as sufficient and none of these were optimal. If HIER was applied, 4 out of 75 protocols (56 %) were assessed as sufficient, out of which 11 (15 %) were optimal. A significant difference in the overall performance for the EP4 was also related to the HIER buffer and thus the IHC platform applied. If HIER was based on TRS low ph 6.1 (Dako) and subsequently IHC was performed by an open IHC platform such as the Autostainer (Dako or LabVision) 8 out of 33 laboratories (85 %) produced a sufficient staining, out of which 11 (33 %) were optimal. Using the fully automated platform BenchMark XT or BenchMark Ultra, Ventana, and HIER based on Cell Conditioning 1, ph 8.5, 19 out of 19 protocols were assessed as insufficient. As an alternative to TRS low ph 6.1, Dako, it was observed that HIER based on DIVA decloaker solution ph 6., Biocare gave an optimal staining result in out of protocols for the EP4. The most successful and robust assay for Ep-CAM based on the EP4 in this assessment was obtained by the Ready-To-Use (RTU) system from Dako giving a pass rate of 93 % (13 out of 14 laboratories)out of which 11 % (1 laboratory) were assessed as optimal. In comparison the RTU system from Ventana based on the same mab gave a pass rate of 13 % (1 out of 8 laboratories) and none were assessed as optimal. The MOC31 and VU-1D9 gave a slightly different staining pattern in both the normal kidney and in the two renal clear cell carcinomas. In the kidney the epithelial cells of the collecting tubules showed a moderate to Nordic Immunohistochemical Quality Control, Ep-CAM run 3 011 Page of 5

strong membranous staining similar to the pattern seen for the EP4, but also an increased staining in the basolateral membranes of the epithelial cells of the proximal tubules. The MOC31 and VU-1D9 also typically labelled a higher proportion of the neoplastic cells in the two renal cell carcinomas. For the mab MOC31 an optimal staining typically was obtained by HIER in e.g. TRS low ph 6.1 (Dako), but an optimal result could also be obtained by other HIER buffers with an alkaline ph as EDTA ph 8 and TRS High ph 9 (Dako) and by the use of proteolytic pre-treatment. The VU-1D9 was the only marker for Ep-CAM giving an optimal staining result on both an open IHC platform, Autostainer (LabVision), using HIER in Citrate ph 6 and a fully automated platform, BenchMark Ultra (Ventana), using HIER in Cell Conditioning 1. Kidney was the most reliable positive control for Ep-CAM. A moderate to strong membranous staining must be seen in the epithelial cells of the collecting ducts, whereas optimally an at least weak basolateral membranous staining should be seen in the epithelial cells of the proximal tubules. Appendix can not be recommended as the columnar epithelial cells have a high expression of EP-CAM and thus will not identify a protocol with a too low sensitivity. This was the 3rd NordiQC assessment of Ep-CAM (see table 3). A significant decrease in the proportion of sufficient results was seen in this run compared to the previous runs. This is most likely related to a combination of more challenging material circulated and many new laboratories participating for the first time. For the laboratories participating for the first time the pass rate was 37 % (5 out of 67), whereas the pass rate was 51 % (38 out of 74 laboratories) for the laboratories participating in previous runs. Table. Proportion of sufficient results for EpCAM in the four NordiQC runs performed Run 17 006 Run 3 008 Run 3 011 Participants, n= 74 78 141 Sufficient results 54 % 63 % 45 % Conclusion The s EP4, MOC31 and VU-1D9 can all be used for the demonstration of Ep-CAM. HIER in TRS low ph 6.1 (Dako) or Diva Decloaker ph 6. (Biocare) seems mandatory for an optimal performance of the EP4. For the s MOC31 and VU-1D5, HIER in either an alkaline buffer or a non-alkaline buffer such as Citrate ph 6 could be used to obtain an optimal performance. Kidney is a recommendable positive control: A moderate to strong membranous staining must be seen in the epithelial cells of the renal collecting tubules while an at least weak membranous staining should be seen in the epithelial cells of the proximal tubules. Fig. 1a Optimal staining for Ep-CAM in the appendix using the mab clone EP4 optimally calibrated and with HIER in DIVA epitope retrieval solution ph 6. (Biocare). The enterocytes show a strong distinct predominantly membranous staining. Macrophages having engulfed epithelial cells show an intracytoplasmic staining. Fig. 1b Staining for Ep-CAM in the appendix using an insufficient protocol based on the ER4 with HIER in an alkaline buffer, CC1 ph 8.5 Ventana, same field as in Fig. 1a. The enterocytes show a strong distinct predominantly membranous staining. However also compare with Figs. b 4b, same protocol. As an insufficient staining for Ep-CAM was seen in both renal cell carcinomas, appendix can not be recommended as a positive control due to a too high expression of Ep-CAM. Nordic Immunohistochemical Quality Control, Ep-CAM run 3 011 Page 3 of 5

Fig. a Optimal staining for Ep-CAM of the normal kidney using same protocol as in Fig. 1a. The epithelial cells of the renal collecting tubules and the Bowman capsule show a moderate to strong membranous staining, while the epithelial cells of the proximale tubules only show a weak predominantly basolateral reaction. Fig. b Insufficient staining for Ep-CAM of the normal kidney using same protocol as in Fig. 1b, same field as in Fig. a. Only the epithelial cells of the collecting tubules are demonstrated. Also compare with Figs. 3b and 4b. Fig. 3a Optimal staining for Ep-CAM in the renal clear cell carcinoma no. 5 using same protocol as in Figs. 1a - a. The majority of the neoplastic cells show a moderate and distinct membranous reaction. No background reaction is seen. Fig. 3b Insufficient staining staining for Ep-CAM in the renal clear cell carcinoma no. 5 using same protocol as in Figs. 1b b, same field as in Fig. 3b. The neoplastic cells are all false negative. Nordic Immunohistochemical Quality Control, Ep-CAM run 3 011 Page 4 of 5

Fig. 4a Fig. 4b Optimal Ep-CAM staining of the renal cell carcinoma no. 6 using Insufficient Ep-CAM staining of the renal cell carcinoma no. 6 same protocol as in Figs. 1a 3a. Scattered neoplastic cells using same protocol as in Figs. 1b 3b, same field as in Fig. show a weak to moderate distinct membranous reaction. 4a. The neoplastic cells are all false negative. SN/MV/LE 30-6-011 Nordic Immunohistochemical Quality Control, Ep-CAM run 3 011 Page 5 of 5